{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:38:33Z","timestamp":1778931513393,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic beta-cells are selectively destroyed by the host immune system in type 1 diabetes. Thus, drugs that preserve beta-cell mass and\/or function have the potential to prevent or slow the progression of this disease. We recently reported that the use-dependent sodium channel blocker, carbamazepine, protects beta-cells from inflammatory cytokines<jats:italic>in vitro<\/jats:italic>. Here, we tested the effects of carbamazepine treatment in female non-obese diabetic (NOD) mice by supplementing LabDiet 5053 with 0.5% w\/w carbamazepine to achieve serum carbamazepine levels of 14.98\u2009\u00b1\u20093.19\u2009\u00b5M. Remarkably, diabetes incidence over 25 weeks, as determined by fasting blood glucose, was ~50% lower in carbamazepine treated animals. Partial protection from diabetes in carbamazepine-fed NOD mice was also associated with improved glucose tolerance at 6 weeks of age, prior to the onset of diabetes in our colony. Less insulitis was detected in carbamazepine treated NOD mice at 6 weeks of age, but we did not observe differences in CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>T cell composition in the pancreatic lymph node, as well as circulating markers of inflammation. Taken together, our results demonstrate that carbamazepine reduces the development of type 1 diabetes in NOD mice by maintaining functional beta-cell mass.<\/jats:p>","DOI":"10.1038\/s41598-018-23026-w","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T10:58:23Z","timestamp":1520593103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Carbamazepine, a beta-cell protecting drug, reduces type 1 diabetes incidence in NOD mice"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8681-8257","authenticated-orcid":false,"given":"Jason T. C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Shanina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung Ning","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-9433","authenticated-orcid":false,"given":"James D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"23026_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaut.2016.03.008","volume":"71","author":"MR Ehlers","year":"2016","unstructured":"Ehlers, M. R. Strategies for clinical trials in type 1 diabetes. J Autoimmun 71, 88\u201396, https:\/\/doi.org\/10.1016\/j.jaut.2016.03.008 (2016).","journal-title":"J Autoimmun"},{"key":"23026_CR2","doi-asserted-by":"publisher","first-page":"e0168839","DOI":"10.1371\/journal.pone.0168839","volume":"11","author":"S Lamprianou","year":"2016","unstructured":"Lamprianou, S. et al. Glibenclamide Prevents Diabetes in NOD Mice. PloS one 11, e0168839, https:\/\/doi.org\/10.1371\/journal.pone.0168839 (2016).","journal-title":"PloS one"},{"key":"23026_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1210\/me.2013-1257","volume":"28","author":"YH Yang","year":"2014","unstructured":"Yang, Y. H., Vilin, Y. Y., Roberge, M., Kurata, H. T. & Johnson, J. D. Multiparameter screening reveals a role for Na+ channels in cytokine-induced beta-cell death. Molecular endocrinology 28, 406\u2013417, https:\/\/doi.org\/10.1210\/me.2013-1257 (2014).","journal-title":"Molecular endocrinology"},{"key":"23026_CR4","doi-asserted-by":"publisher","first-page":"150306","DOI":"10.1098\/rsos.150306","volume":"2","author":"M Szabat","year":"2015","unstructured":"Szabat, M. et al. High-content screening identifies a role for Na(+) channels in insulin production. Royal Society open science 2, 150306, https:\/\/doi.org\/10.1098\/rsos.150306 (2015).","journal-title":"Royal Society open science"},{"key":"23026_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cmet.2014.12.010","volume":"21","author":"SM Burns","year":"2015","unstructured":"Burns, S. M. et al. High-throughput luminescent reporter of insulin secretion for discovering regulators of pancreatic Beta-cell function. Cell Metab 21, 126\u2013137, https:\/\/doi.org\/10.1016\/j.cmet.2014.12.010 (2015).","journal-title":"Cell Metab"},{"key":"23026_CR6","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1113\/jphysiol.2014.274209","volume":"592","author":"Q Zhang","year":"2014","unstructured":"Zhang, Q. et al. Na+ current properties in islet alpha- and beta-cells reflect cell-specific Scn3a and Scn9a expression. J Physiol 592, 4677\u20134696, https:\/\/doi.org\/10.1113\/jphysiol.2014.274209 (2014).","journal-title":"J Physiol"},{"key":"23026_CR7","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.2337\/db14-1223","volume":"64","author":"PJ Lincez","year":"2015","unstructured":"Lincez, P. J., Shanina, I. & Horwitz, M. S. Reduced expression of the MDA5 Gene IFIH1 prevents autoimmune diabetes. Diabetes 64, 2184\u20132193, https:\/\/doi.org\/10.2337\/db14-1223 (2015).","journal-title":"Diabetes"},{"key":"23026_CR8","doi-asserted-by":"publisher","first-page":"e17049","DOI":"10.1371\/journal.pone.0017049","volume":"6","author":"C King","year":"2011","unstructured":"King, C. & Sarvetnick, N. The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PloS one 6, e17049, https:\/\/doi.org\/10.1371\/journal.pone.0017049 (2011).","journal-title":"PloS one"},{"key":"23026_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1017\/neu.2013.23","volume":"26","author":"NZ Kara","year":"2014","unstructured":"Kara, N. Z. et al. Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice. Acta Neuropsychiatr 26, 29\u201334, https:\/\/doi.org\/10.1017\/neu.2013.23 (2014).","journal-title":"Acta Neuropsychiatr"},{"key":"23026_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1152\/japplphysiol.00514.2007","volume":"104","author":"AF Maree","year":"2008","unstructured":"Maree, A. F., Komba, M., Finegood, D. T. & Edelstein-Keshet, L. A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB\/c) and diabetes-prone (NOD) mice. Journal of applied physiology 104, 157\u2013169, https:\/\/doi.org\/10.1152\/japplphysiol.00514.2007 (2008).","journal-title":"Journal of applied physiology"},{"key":"23026_CR11","doi-asserted-by":"publisher","first-page":"E323","DOI":"10.1152\/ajpendo.00284.2009","volume":"297","author":"E Manesso","year":"2009","unstructured":"Manesso, E. et al. Dynamics of beta-cell turnover: evidence for beta-cell turnover and regeneration from sources of beta-cells other than beta-cell replication in the HIP rat. American journal of physiology. Endocrinology and metabolism 297, E323\u2013330, https:\/\/doi.org\/10.1152\/ajpendo.00284.2009 (2009).","journal-title":"American journal of physiology. Endocrinology and metabolism"},{"key":"23026_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1124\/mol.116.103861","volume":"90","author":"M Velasco","year":"2016","unstructured":"Velasco, M., Diaz-Garcia, C. M., Larque, C. & Hiriart, M. Modulation of Ionic Channels and Insulin Secretion by Drugs and Hormones in Pancreatic Beta Cells. Molecular pharmacology 90, 341\u2013357, https:\/\/doi.org\/10.1124\/mol.116.103861 (2016).","journal-title":"Molecular pharmacology"},{"key":"23026_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/BF01868466","volume":"116","author":"DM Pressel","year":"1990","unstructured":"Pressel, D. M. & Misler, S. Sodium channels contribute to action potential generation in canine and human pancreatic islet B cells. The Journal of membrane biology 116, 273\u2013280 (1990).","journal-title":"The Journal of membrane biology"},{"key":"23026_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","volume":"9","author":"M Mantegazza","year":"2010","unstructured":"Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S. & Avoli, M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9, 413\u2013424, https:\/\/doi.org\/10.1016\/S1474-4422(10)70059-4 (2010).","journal-title":"Lancet Neurol"},{"key":"23026_CR15","doi-asserted-by":"publisher","first-page":"20942","DOI":"10.1074\/jbc.M113.470948","volume":"288","author":"PC Chen","year":"2013","unstructured":"Chen, P. C. et al. Carbamazepine as a novel small molecule corrector of trafficking-impaired ATP-sensitive potassium channels identified in congenital hyperinsulinism. The Journal of biological chemistry 288, 20942\u201320954, https:\/\/doi.org\/10.1074\/jbc.M113.470948 (2013).","journal-title":"The Journal of biological chemistry"},{"key":"23026_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4161\/chan.29117","volume":"8","author":"Q Zhou","year":"2014","unstructured":"Zhou, Q. et al. Carbamazepine inhibits ATP-sensitive potassium channel activity by disrupting channel response to MgADP. Channels 8, 376\u2013382 (2014).","journal-title":"Channels"},{"key":"23026_CR17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0026-895X(25)08760-7","volume":"47","author":"P Granger","year":"1995","unstructured":"Granger, P. et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular pharmacology 47, 1189\u20131196 (1995).","journal-title":"Molecular pharmacology"},{"key":"23026_CR18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0028-3908(99)00058-1","volume":"38","author":"AF Ambrosio","year":"1999","unstructured":"Ambrosio, A. F. et al. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38, 1349\u20131359 (1999).","journal-title":"Neuropharmacology"},{"key":"23026_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1126\/science.1190354","volume":"329","author":"T Hidvegi","year":"2010","unstructured":"Hidvegi, T. et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329, 229\u2013232, https:\/\/doi.org\/10.1126\/science.1190354 (2010).","journal-title":"Science"},{"key":"23026_CR20","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.R109.072181","volume":"285","author":"M Renna","year":"2010","unstructured":"Renna, M., Jimenez-Sanchez, M., Sarkar, S. & Rubinsztein, D. C. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. The Journal of biological chemistry 285, 11061\u201311067, https:\/\/doi.org\/10.1074\/jbc.R109.072181 (2010).","journal-title":"The Journal of biological chemistry"},{"key":"23026_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cmet.2008.08.013","volume":"8","author":"HS Jung","year":"2008","unstructured":"Jung, H. S. et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell metabolism 8, 318\u2013324, https:\/\/doi.org\/10.1016\/j.cmet.2008.08.013 (2008).","journal-title":"Cell metabolism"},{"key":"23026_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00125-011-2350-y","volume":"55","author":"W Quan","year":"2012","unstructured":"Quan, W. et al. Autophagy deficiency in beta cells leads to compromised unfolded protein response and progression from obesity to diabetes in mice. Diabetologia 55, 392\u2013403, https:\/\/doi.org\/10.1007\/s00125-011-2350-y (2012).","journal-title":"Diabetologia"},{"key":"23026_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cmet.2008.08.009","volume":"8","author":"C Ebato","year":"2008","unstructured":"Ebato, C. et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell metabolism 8, 325\u2013332, https:\/\/doi.org\/10.1016\/j.cmet.2008.08.009 (2008).","journal-title":"Cell metabolism"},{"key":"23026_CR24","doi-asserted-by":"publisher","first-page":"e0172567","DOI":"10.1371\/journal.pone.0172567","volume":"12","author":"HL Hayes","year":"2017","unstructured":"Hayes, H. L. et al. Delayed apoptosis allows islet beta-cells to implement an autophagic mechanism to promote cell survival. PloS one 12, e0172567, https:\/\/doi.org\/10.1371\/journal.pone.0172567 (2017).","journal-title":"PloS one"},{"key":"23026_CR25","doi-asserted-by":"publisher","first-page":"27664","DOI":"10.1074\/jbc.M109.041616","volume":"284","author":"K Fujimoto","year":"2009","unstructured":"Fujimoto, K. et al. Autophagy regulates pancreatic beta cell death in response to Pdx1 deficiency and nutrient deprivation. The Journal of biological chemistry 284, 27664\u201327673, https:\/\/doi.org\/10.1074\/jbc.M109.041616 (2009).","journal-title":"The Journal of biological chemistry"},{"key":"23026_CR26","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00125-016-3929-0","volume":"59","author":"IC Chou","year":"2016","unstructured":"Chou, I. C. et al. Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study. Diabetologia 59, 1196\u20131203, https:\/\/doi.org\/10.1007\/s00125-016-3929-0 (2016).","journal-title":"Diabetologia"},{"key":"23026_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.eplepsyres.2015.05.008","volume":"115","author":"MR Keezer","year":"2015","unstructured":"Keezer, M. R., Novy, J. & Sander, J. W. Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics. Epilepsy research 115, 55\u201357, https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.05.008 (2015).","journal-title":"Epilepsy research"},{"key":"23026_CR28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.seizure.2012.01.003","volume":"21","author":"R Ramakrishnan","year":"2012","unstructured":"Ramakrishnan, R. & Appleton, R. Study of prevalence of epilepsy in children with type 1 diabetes mellitus. Seizure-Eur J Epilep 21, 292\u2013294, https:\/\/doi.org\/10.1016\/j.seizure.2012.01.003 (2012).","journal-title":"Seizure-Eur J Epilep"},{"key":"23026_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/ana.20830","volume":"59","author":"S Vulliemoz","year":"2006","unstructured":"Vulliemoz, S. & Seeck, M. An association between type 1 diabetes and idiopathic generalized epilepsy. Ann Neurol 59, 728\u2013728, https:\/\/doi.org\/10.1002\/ana.20830 (2006).","journal-title":"Ann Neurol"},{"key":"23026_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00592-011-0268-y","volume":"49","author":"AM Davalli","year":"2012","unstructured":"Davalli, A. M., Perego, C., Folli, F. B. & Bosi, E. Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol 49, 75\u201379, https:\/\/doi.org\/10.1007\/s00592-011-0268-y (2012).","journal-title":"Acta Diabetol"},{"key":"23026_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/01.WNL.0000137341.89781.14","volume":"63","author":"P Raskin","year":"2004","unstructured":"Raskin, P. et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63, 865\u2013873 (2004).","journal-title":"Neurology"},{"key":"23026_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaci.2006.03.005","volume":"118","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. Activation of T cells by carbamazepine and carbamazepine metabolites. The Journal of allergy and clinical immunology 118, 233\u2013241, https:\/\/doi.org\/10.1016\/j.jaci.2006.03.005 (2006).","journal-title":"The Journal of allergy and clinical immunology"},{"key":"23026_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ana.21172","volume":"62","author":"JA Black","year":"2007","unstructured":"Black, J. A., Liu, S., Carrithers, M., Carrithers, L. M. & Waxman, S. G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 62, 21\u201333, https:\/\/doi.org\/10.1002\/ana.21172 (2007).","journal-title":"Ann Neurol"},{"key":"23026_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1528-1157.1994.tb02934.x","volume":"35","author":"CE Andrade-Mena","year":"1994","unstructured":"Andrade-Mena, C. E., Sardo-Olmedo, J. A. & Ramirez-Lizardo, E. J. Effects of carbamazepine on murine humoral and cellular immune responses. Epilepsia 35, 205\u2013208 (1994).","journal-title":"Epilepsia"},{"key":"23026_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","volume":"29","author":"JL Herranz","year":"1988","unstructured":"Herranz, J. L., Armijo, J. A. & Arteaga, R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 29, 794\u2013804 (1988).","journal-title":"Epilepsia"},{"key":"23026_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/archneur.1968.00480020015001","volume":"19","author":"JM Killian","year":"1968","unstructured":"Killian, J. M. & Fromm, G. H. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol 19, 129\u2013136 (1968).","journal-title":"Use of side effects. Arch Neurol"},{"issue":"3","key":"23026_CR37","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1111\/j.1528-1157.1987.tb05780.x","volume":"28","author":"JM Pellock","year":"1987","unstructured":"Pellock, J. M. Carbamazepine side effects in children and adults. Epilepsia 28(3), S64\u201370 (1987).","journal-title":"Epilepsia"},{"key":"23026_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cmet.2015.10.016","volume":"23","author":"M Szabat","year":"2016","unstructured":"Szabat, M. et al. Reduced Insulin Production Relieves Endoplasmic Reticulum Stress and Induces beta Cell Proliferation. Cell Metab 23, 179\u2013193, https:\/\/doi.org\/10.1016\/j.cmet.2015.10.016 (2016).","journal-title":"Cell Metab"},{"key":"23026_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nature methods 9, 676\u2013682, https:\/\/doi.org\/10.1038\/nmeth.2019 (2012).","journal-title":"Nature methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23026-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23026-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23026-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:46:52Z","timestamp":1751474812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23026-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23026-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"6 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4588"}}